Brainstorm Health: GSK Tesaro Deal, VR Medical Education, Bluebird Bio-9.66

Hello, readers. I hope you had a wonderful weekend.

On Monday, GlaxoSmithKline CEO Emma Walmsley made yet another significant mark on her company’s future, placing a $5.1 billion bet to acquire the cancer-focused biotech Tesaro. Tesaro stock soared 60% on the news while GSK shares slid 8% in Monday afternoon trading.

Original source

Add comment

Please Sign in to be able to leave comments.